

## Special Issue

# Vaccine Adjuvants and Immunological Considerations in the Pre- and Post-COVID Era

### Message from the Guest Editor

While highly infectious diseases such as pertussis, rubella and polio are an illustrious part of history, infant mortality rate in the US was over 20 percent only a century ago. Since the discovery, development and widespread use of vaccines, these diseases have been contained. Understanding the crucial factors underlying protective immunity by a wide variety of vaccines came later, in tandem with far-reaching discoveries including dendritic cells, toll-like receptors and cell-mediated immunity. Now, the societal urgency of the COVID-19 pandemic has impacted vaccine research. The “bed-to-benchside” trope has demonstrated its plausibility with the widespread implementation of mRNA-based or LNP-derived vaccines. However, fundamental research on its immunological mode of action must catch up when considering its use beyond SARS-CoV-2. Adjuvant research has shown its capacity to boost and maintain the immunological efficacy of the newest vaccine modalities. As new modalities are now being explored, understanding the adjuvanticity of vaccines and the combination with known and novel adjuvants is crucial to fight the diseases of tomorrow, while limiting side effects.

### Guest Editor

Dr. Sjoerd T. Schetters

Department of Molecular Cell Biology and Immunology, Vrije Universiteit Amsterdam, 1081 HZ Amsterdam, The Netherlands

### Deadline for manuscript submissions

closed (30 June 2023)



## Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/143280](https://mdpi.com/si/143280)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).